SIGHT.PA stock: GenSight Biologics €0.0838 after-hours, earnings 20 Mar 2026

SIGHT.PA stock opened after-hours at €0.0838, down 1.30% as investors digest GenSight Biologics S.A. results due 20 Mar 2026. The clinical-stage biotech reports on earnings today amid thin liquidity and heavy year-to-date declines. We focus on the numbers that move price: cash runway, EPS of -0.13, and trial milestones for LUMEVOQ and GS030.

After-hours price action and immediate drivers

GenSight Biologics S.A. (SIGHT.PA) trades on EURONEXT in Europe and finished regular hours at €0.0838, with after-hours moves keeping volatility elevated. Volume today was 630,511.00 shares versus an average of 1,924,885.00, showing below-average liquidity that can amplify earnings reactions.

Investors should watch the company’s earnings announcement scheduled on 20 Mar 2026 and any clinical update on LUMEVOQ (GS010). Clinical readouts or trial timelines typically drive large intraday moves for small-cap biotech names.

Fundamentals snapshot: losses, liquidity and valuation

GenSight reports EPS -0.13 and a trailing PE of -0.64, reflecting ongoing losses as R&D continues. Market capitalization stands at €15,924,435.00, with 190,029,052.00 shares outstanding.

Key ratios highlight stress versus peers: SIGHT.PA current ratio is 0.11 versus the healthcare/biotech sector average 2.15, signaling short-term liquidity risk. Price-to-sales is 16.85, far above typical biotech comparables, which increases sensitivity to milestone delivery.

Clinical and revenue catalysts tied to SIGHT.PA earnings

GenSight’s near-term value drivers are trial progress and commercialization plans for LUMEVOQ and the GS030 programme. Positive Phase III signals or regulatory clarity would materially improve prospects for SIGHT.PA stock.

Conversely, delays or negative safety/efficacy data would likely pressure the share price given limited cash buffers and high enterprise value relative to revenue (EV/Sales 36.69).

Technicals and trading signals for SIGHT.PA stock

Short-term indicators are mixed: RSI 46.32 and ADX 47.58 suggest a strong trend but neutral momentum. Bollinger Bands range €0.07–€0.10, highlighting low absolute price levels but consistent volatility bands.

Traders should note the 50-day average €0.09 and 200-day €0.13. A decisive move above €0.09 with volume above the 50-day average would be constructive for short-term momentum.

Meyka Stock Grade and model forecast

Meyka AI rates SIGHT.PA with a score out of 100: 72.35 (Grade B+, Suggestion: BUY). This grade factors in S&P 500 and sector comparisons, financial growth, key metrics, forecasts, analyst consensus, and fundamentals. Grades are informational and not financial advice.

Meyka AI’s forecast model projects a monthly price of €0.07 (implied downside -16.47% vs current €0.0838) and a 1-year model figure of €0.0137 (implied downside -83.65%). Forecasts are model-based projections and not guarantees. For full data see Meyka coverage: GenSight SIGHT.PA on Meyka.

News flow and recommended watchlist ahead of the report

Follow results headlines, trial milestone statements, and any capital raise activity. Reuters and Investing.com publish live updates and historical charts that help confirm market reaction. Reuters company page and Investing.com coverage are primary external sources for live quotes.

Monitor corporate commentary on cash runway, upcoming catalysts for LUMEVOQ and GS030, and any guidance on partnerships or licensing that would change the company’s funding outlook.

Final Thoughts

Key takeaways for SIGHT.PA stock: the share price of €0.0838 reflects deep discounting of GenSight Biologics’ pipeline value and clear liquidity constraints. The company posts EPS -0.13 and a market cap of €15,924,435.00, while the current ratio of 0.11 flags short-term cash risk versus sector averages. Clinically driven upside is concentrated in LUMEVOQ Phase III and GS030 progress; positive data or a near-term partnership could trigger sharp upside. Meyka AI’s scenario targets set a conservative bear case at €0.04 (implied downside -52.28%), a base case at €0.09 (implied upside 7.40%), and a bull case at €0.20 (implied upside 138.76%). Our forecast model projects monthly €0.07 (down 16.47% vs current). Investors should treat today’s earnings as a binary catalyst and size positions for high volatility. Meyka AI-powered market analysis flags this as speculative with high news sensitivity; conduct further due diligence before trading.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.